Orchid Pharma Limited

Material Risks

AI Risk Summary

**Orchid Pharma Limited – Financial Risk Summary** Orchid Pharma faces critical compliance exposure with a maximal 10.0/10 compliance risk score and estimated remediation costs of ₹2–6 crore, primarily driven by unclear Extended Producer Responsibility (EPR) applicability and potential SEBI BRSR Core non-disclosure penalties including enforcement action and delisting risk for large-cap pharmaceutical firms. Water intensity (5.0/10) and GHG intensity (5.0/10) represent moderate operational exposure in a capital-intensive API manufacturing sector, though the absence of reported Scope 1/2 emissions data itself signals disclosure gaps that amplify regulatory vulnerability. The highest financial exposure stems from EPR liability (6.5/10 risk), which remains unquantified but could trigger significant packaging take-back obligations and associated logistics costs once regulatory clarity emerges under revised Extended Producer Responsibility Rules. Immediate priority: establish EPR compliance roadmap, quantify scope 1/2 emissions (currently unreported), and align disclosures with SEBI BRSR Core Expansion requirements to mitigate delisting

Source: Orchid Pharma Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.